vedolizumab

03/01/2014 - "Vedolizumab, an α4β7 antibody, has completed phase 3 trials with very positive results especially for ulcerative colitis. "
02/01/2015 - "In phase III clinical trials, patients with ulcerative colitis had significantly higher rates of clinical response and clinical remission when treated with vedolizumab than when receiving placebo at both 6 and 52 weeks. "
08/08/2014 - "Moderate to high quality data from four studies shows that vedolizumab is superior to placebo for induction of clinical remission and response and endoscopic remission in patients with moderate to severely active ulcerative colitis and prevention of relapse in patients with quiescent ulcerative colitis. "
01/01/2023 - "Vedolizumab showed good safety and effectiveness at inducing remission in children with IBD at 14 weeks, especially those with ulcerative colitis. "
08/08/2014 - "Moderate quality data from one study suggests that vedolizumab is superior to placebo for prevention of relapse in patients with quiescent ulcerative colitis. "

01/01/2023 - "High-certainty data across four induction and three maintenance trials demonstrate that vedolizumab is superior to placebo in the induction and maintenance of remission in Crohn's disease. "
02/01/2015 - "In the Crohn's disease study that included maintenance treatment, vedolizumab was significantly more effective at 52 weeks than placebo in both endpoints (clinical remission was the only primary endpoint in the maintenance study). "
08/22/2013 - "At week 6, a total of 14.5% of the patients in cohort 1 who received vedolizumab and 6.8% who received placebo were in clinical remission (i.e., had a score on the Crohn's Disease Activity Index [CDAI] of ≤150, with scores ranging from 0 to approximately 600 and higher scores indicating greater disease activity) (P=0.02); a total of 31.4% and 25.7% of the patients, respectively, had a CDAI-100 response (≥100-point decrease in the CDAI score) (P=0.23). "
01/01/2020 - "Editorial: is vedolizumab effective for perianal Crohn's disease?"
01/01/2018 - "Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. "

01/01/2018 - "The humanized form of Rh-α4β7, vedolizumab, is a highly effective treatment for inflammatory bowel disease. "
10/01/2020 - "Inflammatory bowel disease (IBD) can be successfully treated with vedolizumab. "
02/01/2020 - "Although the treatment is beneficial for inflammatory bowel disease (IBD), the effects of vedolizumab on extraintestinal manifestations (EIMs) have not been well described. "
03/01/2020 - "The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammatory bowel disease (IBD) and demonstrated a favorable safety profile, suggesting it may be advantageous in older patients at greater risk of treatment-related complications. "
01/01/2022 - "Higher serum concentrations of vedolizumab have been associated with improved outcomes in inflammatory bowel disease. "

01/01/2023 - "On multivariable analyses, prior antitumor necrosis factor (hazard ratio, 0.72; 95% confidence interval, 0.49-0.99) and vedolizumab exposure (hazard ratio, 0.65; 95% confidence interval, 0.48-0.88) were independently associated with lower likelihoods of achieving endoscopic remission. "
03/13/2020 - "Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients."
01/01/2021 - "Nine studies were included, comprising 830 patients, of which 81% were previously treated with anti-tumour necrosis factor (TNF) and 57% with vedolizumab. "
01/01/2022 - "While therapeutic drug monitoring has a proven clinical utility for tumour necrosis factor antagonists, the available guidance for therapeutic drug monitoring and dose escalation of vedolizumab is rather limited. "
06/01/2021 - "Of 114 included patients, 107 (94%) had failed ≥ 1 and 58 (51%) ≥ 2 biological agents (anti-tumour necrosis factor [aTNF] agents or vedolizumab). "

02/01/2020 - "Data indicate that UC patients with distal or left-sided colitis are more likely to achieve remission than patients with extensive colitis following vedolizumab treatment."
01/01/2019 - "We searched PubMed, Scopus and conference abstracts (Digestive Disease Week, European Crohn's and Colitis Organization, and United European Gastroenterology Week), through December 2017, for experimental or observational cohort studies of vedolizumab use in adult patients with CD or UC; we identified studies that provided sufficient data to determine the incidence rate of loss of response among initial responders and the ability of dose intensification to restore response. "
11/01/2023 - "Der humanisierte monoklonale anti-α4β7-Integrin-Antikörper Vedolizumab ist eine von mehreren biologischen Therapieoptionen bei moderaten und schweren Verläufen von Colitis ulcerosa und Morbus Crohn. "
01/01/2023 - "Iatrogenes Kaposi-Sarkom unter Vedolizumab bei Colitis ulcerosa."
02/13/2022 - "This case report supports vedolizumab use in treating severe colitis which failed to resolve with first- and second-line immunosuppressive therapy."